113 related articles for article (PubMed ID: 24397920)
1. Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome.
Pignatta S; Arienti C; Zoli W; Di Donato M; Castoria G; Gabucci E; Casadio V; Falconi M; De Giorgi U; Silvestrini R; Tesei A
Mol Cell Endocrinol; 2014 Jan; 382(1):314-324. PubMed ID: 24397920
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
6. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
[TBL] [Abstract][Full Text] [Related]
7. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
9. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
10. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
[TBL] [Abstract][Full Text] [Related]
11. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
[TBL] [Abstract][Full Text] [Related]
12. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
[TBL] [Abstract][Full Text] [Related]
13. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.
Wang T; Alavian MR; Goel HL; Languino LR; Fitzgerald TJ
Prostate; 2008 Dec; 68(16):1734-42. PubMed ID: 18729104
[TBL] [Abstract][Full Text] [Related]
15. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.
Bouchal J; Baumforth KR; Sváchová M; Murray PG; von Angerer E; Kolár Z
J Pharm Pharmacol; 2005 Jan; 57(1):83-92. PubMed ID: 15638997
[TBL] [Abstract][Full Text] [Related]
16. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
17. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
18. Novel role of androgens in mitochondrial fission and apoptosis.
Choudhary V; Kaddour-Djebbar I; Lakshmikanthan V; Ghazaly T; Thangjam GS; Sreekumar A; Lewis RW; Mills IG; Bollag WB; Kumar MV
Mol Cancer Res; 2011 Aug; 9(8):1067-77. PubMed ID: 21724752
[TBL] [Abstract][Full Text] [Related]
19. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
Makkonen H; Kauhanen M; Jääskeläinen T; Palvimo JJ
Mol Cell Endocrinol; 2011 Jan; 331(1):57-65. PubMed ID: 20728506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]